From target identification to drug screening assays for neurodegenerative diseases

Pharmacological Research

Volumn 52, Issue 3, 2005, Pages 245-251

  Zuccato, Chiara ^a   Tartari, Marzia ^a   Goffredo, Donato ^a   Cattaneo, Elena ^a   Rigamonti, Dorotea ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Arcoblu srl   (Italy)

Author keywords

Drug screening; Huntington's disease; Neurodegenerative disease

Indexed keywords

HUNTINGTIN;

ANIMAL CELL; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUNTINGTON CHOREA; IMMUNOCYTOCHEMISTRY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELLS, CULTURED; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NUCLEAR PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 22144485140     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2005.03.010     Document Type: Article

References (70)

1. J.J. Burbaum, and N.H. Sigal New technologies for high-throughput screening Curr Opin Chem Biol 1 1997 72 78
2. S. Frantz, and A. Smith New drug approval for 2002 Nat Rev Drug Discov 2 2003 95 96
3. M.A. Lindsay Target discovery Nat Rev Drug Discov 2 2003 831 838
4. C. Korth, B.C. May, F.E. Cohen, and S.B. Prusiner Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease Proc Natl Acad Sci USA 98 2001 9836 9841
5. C. Andreassi, J. Jarecki, J. Zhou, D.D. Coovert, U.R. Monani, and X. Chen Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients Hum Mol Genet 10 2001 2841 2849
6. M.M. Muqit, and M.B. Feany Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat Rev Neurosci 3 2002 237 243
7. J. Heemskerk, A.J. Tobin, and L.J. Bain Teaching old drugs new tricks Trends Neurosci 25 2002 494 496
8. P.M. Mathisen Gene discovery and validation for neurodegenerative diseases Drug Discov Today 8 2003 39 46
9. L. Roizin, S. Stellar, and J.C. Liu Neuronal nuclear-cytoplasmic changes in Huntington's chorea: electron microscope investigations T.N. Chase N.S. Wexler A. Barbeau Advances in neurology vol. 23 1979 Raven Press New York, USA 95 122
10. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, and C. Hetherington Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 8 1996 493 506
11. Y.J. Kim, Y. Yi, E. Sapp, Y. Wang, B. Cuiffo, and K.B. Kegel Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis Proc Natl Acad Sci USA 98 2001 12784 12789
12. K.R. Bales Neurodegenerative disease research in the 21st Century Drug Discov Today 9 2004 553 556
13. R.A. Fecik, K.E. Frank, E.J. Gentry, S.R. Menon, L.A. Mitscher, and H. Telikepalli The search for orally active medications through combinatorial chemistry Med Res Rev 18 1998 149 185
14. D. Gorse, A. Rees, M. Kaczorek, and R. Lahana Molecular diversity and its analysis Drug Discov Today 4 1999 257 264
15. P. Burkhard, U. Hommel, M. Sanner, and M.D. Walkinshaw The discovery of steroids and other novel FKBP inhibitors using a molecular docking program J Mol Biol 287 1999 853 858
16. S.B. Shuker, P.J. Hajduk, R.P. Meadows, and S.W. Fesik Discovering high-affinity ligands for proteins: SAR by NMR Science 274 1996 1531 1534
17. R. Kiyama, Y. Tamura, F. Watanabe, H. Tsuzuki, M. Ohtani, and M. Yodo Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors J Med Chem 42 1999 1723 1738
18. J.R. Broach, and J. Thorner High-throughput screening for drug discovery Nature 384 1996 14 16
19. L. Silverman, R. Campbell, and J.R. Broach New assay technologies for high-throughput screening Curr Opin Chem Biol 2 1998 397 403
20. M.J. Valler, and D. Green Diversity screening versus focussed screening in drug discovery Drug Discov Today 5 2000 286 293
21. A. Abbott Neurologists strike gold in drug screen effort Nature 417 2002 109
22. V. Heiser, S. Engemann, W. Brocker, I. Dunkel, A. Boeddrich, and S. Waelter Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay Proc Natl Acad Sci USA 99 2002 16400 16406
23. S.K. Pollitt, J. Pallos, J. Shao, U.A. Desai, A.A. Ma, and L.M. Thompson A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor Neuron 40 2003 685 694
24. J.S. Steffan, L. Bodai, J. Pallos, M. Poelman, A. McCampbell, and B.L. Apostol Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila Nature 413 2001 739 743
25. G. Bates Huntingtin aggrgation and toxicity in Huntington's disease Lancet 361 2003 1642 1644
26. E. Cattaneo, D. Rigamonti, C. Zuccato, D. Goffredo, F. Squitieri, and S. Sipione Loss of normal huntingtin function: new developments in Huntington's disease research Trends Neurosci 24 2001 182 188
27. I. Sanchez, C. Mahlke, and J. Yuan Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders Nature 421 2003 373 379
28. C.T. Aiken, J.T. Allan, and E.S. Schweitzer A cell-based screen for drugs to treat Huntington's disease Neurobiol Dis 16 2004 546 555
29. D. Rigamonti, J.H. Bauer, C. De-Fraja, L. Conti, S. Sipione, and C. Sciorati Wild-type huntingtin protects from apoptosis upstream of caspase-3 J Neurosci 20 2000 3705 3713
30. I. Dragatsis, A. Efstratiadis, and S. Zeitlin Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues Development 125 1998 1529 1539
31. Y. Zhang, M. Li, M. Drozda, M. Chen, S. Ren, and R.O. Mejia Sanchez Neurologic diseases J Neurochem 87 2003 101 106
32. F.R. Fusco, C. Zuccato, M. Tartari, A. Martorana, Z. De March, and C. Giampa Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain Eur J Neurosci 18 2003 1093 1102
33. C. Zuccato, A. Ciammola, D. Rigamonti, B.R. Leavitt, D. Goffredo, and L. Conti Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease Science 293 2001 493 498
34. C. Zuccato, M. Tartari, A. Crotti, D. Goffredo, M. Valenza, and L. Conti Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes Nat Genet 35 2003 76 83
35. R.A. Maue, S.D. Kraner, R.H. Goodman, and G. Mandel Neuron-specific expression of the rat brain type II sodium channel gene is directed by upstream regulatory elements Neuron 4 1990 223 231
36. S.D. Kraner, J.A. Chong, H.J. Tsay, and G. Mandel Silencing the type II sodium channel gene: a model for neural-specific gene regulation Neuron 9 1992 37 44
37. + channel genes binds a factor present in nonneuronal cells but not in neuronal cells Neuron 9 1992 45 54
38. J.A. Chong, J. Tapia-Ramirez, S. Kim, J.J. Toledo-Aral, Y. Zheng, and M.C. Boutros REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons Cell 80 1995 949 957
39. C.J. Schoenherr, and D.J. Anderson The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes Science 267 1995 1360 1363
40. V.V. Lunyak, R. Burgess, G.G. Prefontaine, C. Nelson, S.H. Sze, and J. Chenoweth Corepressor-dependent silencing of chromosomal regions encoding neuronal genes Science 298 5599 2002 1747 1752
41. F. Trettel, D. Rigamonti, P. Hildtrich, V. Wheeler, A. Sharp, and F. Persichetti Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells Hum Mol Genet 9 2000 2799 2809
42. S.W. Davies, M. Turmaine, B.A. Cozens, M. DiFiglia, A.H. Sharp, and C.A. Ross Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537 548
43. J.P. Vonsattel, R.H. Myers, T.J. Stevens, R.J. Ferrante, E.D. Bird, and E.P. Richardson Jr. Neuropathological classification of Huntington's disease J Neuropathol Exp Neurol 44 1985 559 577
44. C.A. Gutekunst, S.H. Li, H. Yi, J.S. Mulroy, S. Kuemmerle, and R. Jones Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology J Neurosci 19 1999 2522 2534
45. M.W. Becher Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length Neurobiol Dis 4 1998 387 397
46. R.H. Myers, J.P. Vonsattel, T.J. Stevens, L.A. Cupples, E.P. Richardson, and J.B. Martin Clinical and neuropathologic assessment of severity in Huntington disease Neurology 38 1988 341 347
47. F. Saudou, S. Finkbeiner, D. Devys, and M.E. Greenberg Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions Cell 95 1998 55 66
48. M. Arrasate, S. Mitra, E.S. Schweitzer, M.R. Segal, and S. Finkbeiner Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death Nature 431 2004 805 810
49. N.F. Bence, R.M. Sampat, and R.R. Kopito Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 2001 1552 1555
50. B. Ravikumar, R. Duden, and D.C. Rubinsztein Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy Hum Mol Genet 11 2002 1107 1117
51. Goffredo D, Rigamonti D, Zuccato C, Tartari M, Valenza M, Cattaneo E. Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's disease. Pharm Res, doi:10.1016/j.phrs.2005.01.006.
52. K.K.W. Wang Calpain and caspase: can you tell the difference? Trends Neurosci 23 2000 20 26
53. P. Liston, W.G. Fong, and R.G. Korneluk The inhibitors of apoptosis: there is more to life than Bcl2 Oncogene 22 2003 8568 8580
54. A.V. Panov, C.A. Gutekunst, B.R. Leavitt, M.R. Hayden, J.R. Burke, and W.J. Strittmatter Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines Nat Neurosci 5 2002 731 736
55. C.L. Wellington, R. Singaraja, L. Ellerby, J. Savill, S. Roy, and B. Leavitt Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells J Biol Chem 275 2000 19831 19838
56. A. Kazantsev, E. Preisinger, A. Dranovsky, D. Goldgaber, and D. Housman Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells Proc Natl Acad Sci USA 96 1999 11404 11409
57. J.S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.Z. Zhu, and H. Gohler The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc Natl Acad Sci USA 97 2000 6763 6768
58. F.C. Nucifora Jr., M. Sasaki, M.F. Peters, H. Huang, J.K. Cooper, and M. Yamada Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity Science 291 2001 2423 2428
59. A. McCampbell, J.P. Taylor, A.A. Taye, J. Robitschek, M. Li, and J. Walcott CREB-binding protein sequestration by expanded polyglutamine Hum Mol Genet 9 2000 2197 2202
60. M.K. Perez, H.L. Paulson, S.J. Pendse, S.J. Saionz, N.M. Bonini, and R.N. Pittman Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation J Cell Biol 143 1998 1457 1470
61. T. Shimohata, T. Nakajima, M. Yamada, C. Uchida, O. Onodera, and S. Naruse Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription Nat Genet 26 2000 29 36
62. S. Sipione, D. Rigamonti, M. Valenza, C. Zuccato, L. Conti, and J. Pritchard Early transcriptional profiles in huntingtin inducible striatal cells by microarray analyses Hum Mol Genet 11 2002 1953 1965
63. R. Luthi-Carter, A. Strand, N.L. Peters, S.M. Solano, Z.R. Hollingsworth, and A.S. Menon Decreased expression of striatal signaling genes in a mouse model of Huntington's disease Hum Mol Genet 9 2000 1259 1271
64. R. Luthi-Carter, A.D. Strand, S.A. Hanson, C. Kooperberg, G. Schilling, and A.R. La Spada Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects Hum Mol Genet 11 2002 1927 1937
65. E.Y. Chan, R. Luthi-Carter, A. Strand, S.M. Solano, S.A. Hanson, and M.M. DeJohn Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease Hum Mol Genet 11 2002 1939 1951
66. R.J. Ferrante, J.K. Kubilus, J. Lee, H. Ryu, A. Beesen, and B. Zucker Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice J Neurosci 23 2003 9418 9427
67. M. Hoshino, K. Tagawa, T. Okuda, M. Murata, K. Oyanagi, and N. Arai Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein J Neurochem 87 2003 257 267
68. P. Lawinger, R. Venugopal, Z.S. Guo, A. Immaneni, D. Sengupta, and W. Lu The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells Nat Med 6 2000 826 831
69. Y. Peng, C. Li, L. Chen, S. Sebti, and J. Chen Rescue of mutant p53 transcription function by ellipticine Oncogene 22 2003 4478 4487
70. N.D. Belyaev, I.C. Wood, A.W. Bruce, M. Street, J.B. Trinh, and N.J. Buckley Distinct RE-1 silencing transcription factor-containing complexes interact with different target genes J Biol Chem 279 2004 556 561